Innovative Biomarker Development SphingoTec specializes in developing cutting-edge biomarkers for diagnosing and monitoring acute medical conditions and predicting health risks, presenting opportunities to integrate their solutions into hospital and clinical settings aiming to improve patient management and outcomes.

Recent Product Launches The recent launch of the AFIAS sphingotest penKid assay and the earlier IB10 sphingotest enables real-time evaluation of kidney function, indicating a strong market presence in critical diagnostic testing and potential for expanding into related early detection markets.

Strategic Funding Support Securing €5.46 million in Series C financing from reputable investors like Think.Health Ventures and others highlights strong growth potential and positions SphingoTec for market expansion and development of their biomarker products.

Market Focus and Expansion Headquartered in Germany with recent collaborations and launches in Korea, SphingoTec is positioned to expand its global footprint in critical care diagnostics, offering targeted sales opportunities in international markets and hospital networks.

Financial and Team Profile With revenue between $1M and $10M and a dedicated team of up to 50 employees, SphingoTec offers a nimble organization with growth ambitions, making it attractive for tailored partnerships and strategic sales efforts in the biotech diagnostic sector.